Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 5/20 | 0.38 |
| ▸ | NPY1R | P25929 | 3/20 | 0.38 |
| ▸ | NPY2R | P49146 | 2/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.38 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.38 |
| ▸ | FURIN | P09958 | 2/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL84332 | 1.00 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| SCHEMBL22315797 | 1.00 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| SCHEMBL20739105 | 1.00 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| SCHEMBL20158427 | 1.00 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| SCHEMBL15692085 | 1.00 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| SCHEMBL12944390 | 1.00 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| Hydrochloric Acid SCHEMBL28466191 | 0.99 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| Hydrochloric Acid SCHEMBL28466185 | 0.99 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| SCHEMBL21566843 | 0.97 | SIRT1 (0.41) | NPY4RNPY1RNPY2RNPY5RSPHK1 | |
| SCHEMBL21233409 | 0.93 | HTT (0.38) | SPHK1SPHK2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1583 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4748396-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-NECTIN4 ANTIBODY-DRUG CONJUGATE AND ANTI-PD-1 ANTIBODY AND USE THEREOF | Jiangsu Mabwell Health Pharmaceutical R&D Co., Ltd. (CN) | 2026-05-27 | — | — | EP | claimed |
| EP-4746921-A1 | DRUG CONJUGATES OF IMIDAZOQUINOLINE AMINE DERIVATIVES, COMPOSITIONS AND METHODS THEREOF | Canwell Biotech Limited (CN) | 2026-05-27 | — | — | EP | claimed |
| WO-2026098695-A1 | ANTIBODY LABELING METHOD | 上海睿智医药研究集团有限公司 | 2026-05-15 | — | — | WO | claimed |
| US-20260077056-A1 | LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF | GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) | 2026-03-19 | — | — | US | claimed |
| US-12564641-B2 | Eribulin antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-03-03 | — | — | US | claimed |
| CN-121574249-A | Anti-CD 45 antibodies and conjugates thereof | VOR生物制药股份有限公司 | 2026-02-27 | — | — | CN | claimed |
| WO-2026044039-A2 | ANTI-CD73 ANTIBODIES, CONJUGATES, AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-02-26 | — | — | WO | claimed |
| EP-4692122-A1 | HUMANIZED ANTIBODIES TARGETING EPHA10 | Korea University Research and Business Foundation (KR) | 2026-02-11 | — | — | EP | claimed |
| EP-4673474-A2 | ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2026-01-07 | — | — | EP | claimed |
| US-12514928-B2 | Herboxidiene antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-01-06 | — | — | US | claimed |
| CN-114272389-A | Eribulin-based antibody-drug conjugates and methods of use | 卫材研究发展管理有限公司 | 2022-04-05 | — | — | CN | claimed |
| EP-3972647-A1 | DRUG CONJUGATES AND METHODS OF USING SAME | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2022-03-30 | — | — | EP | claimed |
| CN-114191428-A | Eribulin-based antibody-drug conjugates and methods of use | 卫材研究发展管理有限公司 | 2022-03-18 | — | — | CN | claimed |
| US-20220073907-A1 | TAGLESS ENCODED CHEMICAL LIBRARY | Nanna Therapeutics Limited (GB) | 2022-03-10 | — | — | US | claimed |
| US-20220072137-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATES AND ITS USE | REMEGEN CO., LTD. (CN) | 2022-03-10 | — | — | US | claimed |
| EP-3959242-A1 | ANTHRACYCLINE ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | claimed |
| EP-3958910-A1 | ANTI-CD45 ANTIBODY DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | claimed |
| EP-3946635-A2 | LOCALLY ACTING TOLL-LIKE RECEPTOR 7 (TLR7) AND/OR TLR8 AGONIST IMMUNOTHERAPY COMPOUNDS AND THEIR USES | ALTIMMUNE UK LIMITED (GB) | 2022-02-09 | — | — | EP | claimed |
| EP-0624377-B1 | Lysosomal enzyme-cleavable antitumor drug conjugates | BRISTOL MYERS SQUIBB CO (US) | 2002-01-23 | — | — | EP | claimed |
| EP-0624377-A2 | Lysosomal enzyme-cleavable antitumor drug conjugates | Bristol-Myers Squibb Company (US) | 1994-11-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077056-A1 | LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF | CLTB, LNPEP, DCLRE1A | NPY4R 2814/4885NPY1R 1111/4885NPY2R 1454/4885 |
| US-12564641-B2 | Eribulin antibody-drug conjugates and methods of use | MLLT1, MMGT1, MYADM | NPY4R 2468/4885NPY1R 1058/4885NPY2R 1541/4885 |
| US-20220072137-A1 | LINKER FOR ANTIBODY-DRUG CONJUGATES AND ITS USE | PA2G4, IGSF11, FCGRT | NPY4R 4536/4885NPY1R 4806/4885NPY2R 4745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.